Produced by The National Diabetes Guidelines Group.
The NZSSD working group, with support of the Ministry of Health, develops national up-to-date and evidence-based guidance for the management of type 2 diabetes in adults that will continue to be updated as evidence and practice changes.
In the new 2023 algorithm, lifestyle management and metformin remain the first-line interventions and the recent shift towards reducing CV, renal risk and obesity are emphasised, in addition to improving glycaemic control.
Specific changes to the updated guidance include the following.
Kathy joined Pinnacle earlier this month as clinical diabetes specialist for Waikato, replacing the role previously held by Anne Waterman.
Read morePharmac is now allowing new special authority applications for liraglutide (Victoza) from 1 March 2025. The special authority criteria will be the same as when special authorities were suspended in May 2024. This will again allow prescribing according to national guidelines and best practice. Pharmac has assured the intention is for no further suspensions of special authority criteria for GLP-1 agonists to allow ongoing access for those who meet criteria. To ensure availability, it continues to be important these medications are only prescribed for people with type 2 diabetes mellitus (T2DM). Please contact the Pinnacle diabetes lead in your area if you have any questions.
Read moreThe clinical diabetes specialist in primary care provides clinical mentorship and advice to the practice team in supporting patients with diabetes.
View detailsA guide for clinical management of type 2 diabetes, to support nurses at all levels to develop their knowledge and clinical reasoning in diabetes care.